BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 29774876)

  • 1. The Significance of
    Prieto R; Barrios L; Ebrat-Mancilla E; Martín P; Tejerina E
    Int J Surg Pathol; 2024 Jun; 32(4):649-666. PubMed ID: 37743598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report.
    Lin Z; Xu H; Yang R; Li Z; Zheng H; Zhang Z; Peng J; Zhang X; Qi S; Liu Y; Huang G
    Anticancer Drugs; 2022 Jan; 33(1):100-104. PubMed ID: 34232949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of BRAF Mutation in Glioblastoma.
    Sohail A; Virani QU; Aziz HF; Shamim MS
    J Pak Med Assoc; 2024 Jan; 74(1):185-186. PubMed ID: 38219188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal MR Features of 8 Cases of Epithelioid Glioblastoma.
    Zhao JP; Cui CX; Wang JC; Su HW; Duan CF; Liu XJ
    Biomed Res Int; 2020; 2020():9586806. PubMed ID: 33123592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological, Immunohistochemical and Molecular Genetic Study on Epithelioid Glioblastoma: A Series of Fifteen Cases with Literature Review.
    Zeng Y; Zhu X; Wang Y; Liu B; Yang X; Wang Q; Du J; Ma Y; Lin L; Fu P; Xiao H; Guo QN
    Onco Targets Ther; 2020; 13():3943-3952. PubMed ID: 32440157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma.
    Sugimoto K; Ideguchi M; Kimura T; Kajiwara K; Imoto H; Sadahiro H; Ishii A; Kawano H; Ikeda E; Suzuki M
    Brain Tumor Pathol; 2016 Apr; 33(2):137-46. PubMed ID: 26667174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature.
    Khanna G; Pathak P; Suri V; Sharma MC; Chaturvedi S; Ahuja A; Bhardwaj M; Garg A; Sarkar C; Sharma R
    Pathol Res Pract; 2018 May; 214(5):679-685. PubMed ID: 29615337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
    Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
    Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
    Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
    Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological features for epithelioid glioblastoma: A newly defined tumor by the 2016 World Health Organization Classification of Tumors of the Central Nervous System].
    Li J; Ling X; Lai M; Hu Q; Shan C; Cai L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):398-402. PubMed ID: 29774876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature.
    Li Y; Yang S; Hao C; Chen J; Li S; Kang Z; Kang X; Zhang H; Li W
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776753
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.